Patient Stories in PAH: Sequential Therapy in a FC II Patient

Slides:



Advertisements
Similar presentations
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:
Practical Recommendations for COPD:
Exploring Early Combination Therapy in PAH
CLINICAL DILEMMAS IN HEART FAILURE:
Monitoring and Modifying Treatment in PAH
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
A Paradigm Shift in PAH.
An Update on Oral Prostanoids: Advancing Care for PAH?
Goals of Therapy for Patients With UC
Thrombosis, Cancer, and NOACs
Glaucoma Progression.
A CASE CHALLENGE IN HFrEF:
UNDERSTANDING RISK STRATIFICATION IN PAH:
MANAGING GLAUCOMA:.
Modern Strategies for Basal Insulin Use in T2D
The Latest Data on Oral Prostacyclin Therapy in PAH
Insulin/GLP-1 Agonist Combinations
How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients
All About PAH:.
T2DM and CV Outcomes Trials: A Deep Dive!
PAH Therapy Revisited.
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
Improving Risk Assessment and Early Diagnosis in PAH
Updates in Pulmonary Arterial Hypertension
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
WHO Clinical Classification of PH Complex Cases in PH.
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Evolving Science of PAH Treatment
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Risk Assessment in PAH.
EHL Technologies in Hemophilia Care
A Better Solution For Cancer Patients With VTE?
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
Insulin/GLP-1 Agonist Combinations
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Examining the Latest Evidence in PAH
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
The Importance of Getting the Dose Right in HF
Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Oral Prostanoids and PAH
Navigating Treatment Options in PAH
Preventing Clinical Events in PAH
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
PAH and Prostacyclin Pathways in Focus
PAH-Related Morbidity as a Predictor of Mortality
PAH Treatment.
Cancer-Associated Thrombosis
Pulmonary Arterial Hypertension and Connective Tissue Disease
What's New in PAH?.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
Critical Decision Points in Insomnia
Incorporating Prostacyclins Into Practice
Saving the Day.
Optimal Treatment of PAH
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
AMD Therapy: Where Are We Now and Where Are We Going?
Tailoring Therapy in the Newly Diagnosed Patient With CLL
PAH Pathways: What Do the Data Tell Us?”
Binge Eating Disorder.
Clinical Comparisons in CTEPH
What's New in PAH?.
Practical Recommendations for COPD:
Treatment Advances for RA
The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
What's New in NOACs in AF?.
Translating Data From Trial to Practice
Presentation transcript:

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Program Goals

Case Study 53-Year-Old Man With IPAH

Case Study History

Case Study (cont) History

Now, 17 Months Later

Repeat RHC Findings

Sequential Combination Therapy Recommendations for WHO FC II PAH Patients

Pharmacologic Agents for PAH 3 Pathways

Rationale for Combination Therapy

GRIPHON

GRIPHON Treatment Effect by Subgroup

GRIPHON Titration and Dosing

Primary Composite Endpoint in Patients Grouped by Prespecified Selexipag Individual Maintenance Dose vs Placebo

Case Summary

Abbreviations